WO2025074337 - USE OF ANTI-SIRP-ALPHA ANTIBODIES TO TREAT A LIVER DISEASE OR DISORDER
National phase entry is expected:
Publication Number
WO/2025/074337
Publication Date
10.04.2025
International Application No.
PCT/IB2024/059756
International Filing Date
04.10.2024
Title **
[English]
USE OF ANTI-SIRP-ALPHA ANTIBODIES TO TREAT A LIVER DISEASE OR DISORDER
[French]
UTILISATION D'ANTICORPS ANTI-SIRP-ALPHA POUR TRAITER UNE MALADIE OU UN TROUBLE HÉPATIQUE
Applicants **
BOEHRINGER INGELHEIM INTERNATIONAL GMBH
OSE IMMUNOTHERAPEUTICS SA
Inventors
ARNHOLD, Thomas
MARZIN, Kristell
MONTASERI, Ghazal
PETERSSON, Klas
RUDOLPH, Bryan
SUN, Peng
Priority Data
63/542,986
06.10.2023
US
63/654,791
31.05.2024
US
Application details
| Total Number of Claims/PCT | * |
| Number of Independent Claims | * |
| Number of Priorities | * |
| Number of Multi-Dependent Claims | * |
| Number of Drawings | * |
| Pages for Publication | * |
| Number of Pages with Drawings | * |
| Pages of Specification | * |
| * | |
| Number of Office Actions | * |
| * | |
International Searching Authority |
EPO
* |
| Recordal of a Change of the Applicant's Name/Address |
Change of Applicant's Name and Address
* |
| Type of Assignment |
The Standard Agent's Assignment
* |
| Applicant's Legal Status |
Legal Entity
* |
| * | |
| * | |
| * | |
| * | |
| * | |
| Entry into National Phase under |
Chapter I
* |
| Patent Delivery |
Send the Letters Patent by Courier
* |
| 译文 |
|
* The data is based on automatic recognition. Please verify and amend if necessary.
** IP-Coster compiles data from publicly available sources. If this data includes your personal information, you can contact us to request its removal.
Quotation for National Phase entry
| Country | Stages | Total | |
|---|---|---|---|
| China | Filing, Examination, Granting | 3384 | |
| EPO | Filing, Examination, Granting | 22395 | |
| Japan | Filing, Examination, Granting | 2864 | |
| South Korea | Filing, Examination, Granting | 3550 | |
| USA | Filing, Examination, Granting | 9390 |
Total:
41,583
The term for entry into the National Phase has expired. This quotation is for informational purposes only
Contact Us
Abstract[English]
The present disclosure relates to the treatment of a SIRPα (signal regulatory protein alpha) pathway disease or disorder, such as a liver disease or disorder, by administering an anti-SIRPα antibody or antigen-binding fragment thereof to a subject in need thereof.[French]
La présente divulgation concerne le traitement d'une maladie ou d'un trouble de la voie SIRPα (protéine régulatrice de signal alpha), telle qu'une maladie ou un trouble hépatique, par administration d'un anticorps anti-SIRPα ou d'un fragment de liaison à l'antigène de celui-ci à un sujet en ayant besoin.